Skip to main content
Equibles
KRYS logo

KRYS · Krystal Biotech, Inc. · Earnings Call Transcripts & Audio

Track KRYS — free

Use KRYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KRYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$332.56 -2.50 (-0.75%) At close · Sep 30
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$10.24B
Shares
29.60M
Volume · Sep 30 268.27K Avg daily vol (3M) 373.58K

Krystal Biotech, Inc. Earnings Call Transcripts

Quarterly earnings calls for Krystal Biotech, Inc. (KRYS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $8.56M $80.75M '23 Q3 23-11-06 · $42.14M $8.69M '23 Q4 24-02-26 · $45.25M $932,000 '24 Q1 24-05-06 · $70.28M $15.57M '24 Q2 24-08-05 ▲879.9% $83.84M $27.18M '24 Q3 24-11-04 ▲116.3% $91.14M $45.48M '24 Q4 24-12-31 ▲94.9% $88.18M $35.73M '25 Q1 25-05-06 ▲36.6% $96.04M $38.33M '25 Q2 25-08-04 ▲16.6% $97.80M $79.36M '25 Q3 25-11-03 ▲17.5% $107.11M $51.40M '25 Q4 26-02-17 ▲31.9% $116.36M $55.93M '26 Q1 26-05-04 LATEST ▲24.1% $119.22M $54.77M '26 Q2 26-08-03
Earnings call
FY26 · Q2
2026-08-03
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
Confident tone International Vyjuvec launch momentum U.S. commercial performance and penetration Pricing and reimbursement negotiations
Revenue
$119.22M
▲ 24.1% YoY
Diluted EPS
$1.79
▲ 38.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-04
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Confident tone Pricing and reimbursement negotiations in Europe Vyjuvec U.S. commercial performance Oncology program KB803
Revenue
$116.36M
▲ 31.9% YoY
Diluted EPS
$1.83
▲ 52.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-17
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Confident tone International launches (Germany, France, Japan, Italy) Pricing and reimbursement negotiations Ocular DEB dosing regimen (801/803)
Revenue
$107.11M*
▲ 17.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript
Confident tone Geographic expansion (Europe and Japan) VYJUVEK commercial launch momentum Pipeline development and clinical readouts
Revenue
$97.80M
▲ 16.6% YoY
Diluted EPS
$2.66
▲ 192.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript
Confident tone Vyjuvec launch and U.S. commercial progress Patient compliance dynamics Aesthetics / KB304 / Jun subsidiary
Revenue
$96.04M
▲ 36.6% YoY
Diluted EPS
$1.29
▲ 143.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript
Confident tone VYJUVEK U.S. commercial performance VYJUVEK global expansion (EU/Japan) Clinical pipeline readouts in 2025
Revenue
$88.18M
▲ 94.9% YoY
Diluted EPS
$1.20
▲ 3900% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript
Confident tone VYJUVEK U.S. launch Lung delivery platform pipeline Ophthalmology (B-VEC for DEB eye lesions)
Revenue
$91.14M*
▲ 116.3% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript
Confident tone VYJUVEK launch and revenue Ex-U.S. launches and reimbursement Clinical pipeline readouts
Revenue
$83.84M
▲ 879.9% YoY
Diluted EPS
$0.91
▼ 67.4% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call
Revenue
$70.28M
Diluted EPS
$0.53
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript
Confident tone Patient Compliance and Real-World Experience VYJUVEK U.S. Commercial Launch International Expansion
Revenue
$45.25M
Diluted EPS
$0.03
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript
Confident tone VYJUVEK US launch trajectory and revenue Reimbursement, J-code and gross-to-net dynamics Pipeline and platform breadth
Revenue
$42.14M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Krystal Biotech, Inc. (KRYS) Q3 2023 Earnings Call Transcript
Revenue
$8.56M
Diluted EPS
$2.79
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1711279 CUSIP 501147102 13F (30d) 8 filings 8 filers Visit website Investor relations